Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1986 Dec;66(3):582–589.

Topical cyclosporin A in nickel contact hypersensitivity: results of a preliminary clinical and immunohistochemical investigation.

R D Aldridge, H F Sewell, G King, A W Thomson
PMCID: PMC1542467  PMID: 3552335

Abstract

Four out of eighteen (22%) patients with nickel contact sensitivity showed inhibition of skin patch test responses to the allergen in the presence of topical cyclosporin A (CsA; 5% v/v). No systemic drug absorption or side effects were detected. The clinical response to CsA was accompanied by marked diminution of the T cell infiltrate, although no alteration in the helper/suppressor cell ratio was observed. Expression of the Leu 6 marker on epidermal Langerhans cells and of major histocompatibility complex (MHC) class II antigens (HLA-DR, DQ and DP) on lymphocytes and Langerhans cells was unaffected by topical CsA. The incidence of IL-2 receptor positive lymphocytes in all biopsies was too small to ascertain the influence, if any, of CsA. The prospective use and method of application of CsA in immune contact dermatitis and other immunologically-based skin disorders warrants further evaluation.

Full text

PDF
582

Images in this article

585Fig. 1
on p.585
586Fig. 2
on p.586

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aldridge R. D., Simpson J. G., Whiting P. H., Thomson A. W. Cyclosporin and skin disease. Lancet. 1985 Jan 19;1(8421):160–160. doi: 10.1016/s0140-6736(85)91924-5. [DOI] [PubMed] [Google Scholar]
  2. Aldridge R. D., Thomson A. W., Rankin R., Whiting P. H., Cunningham C., Simpson J. G. Inhibition of contact sensitivity reactions to DNFB by topical cyclosporin application in the guinea-pig. Clin Exp Immunol. 1985 Jan;59(1):23–28. [PMC free article] [PubMed] [Google Scholar]
  3. Bendtzen K., Dinarello C. A. Mechanism of action of cyclosporin A. Effect on T-cell-binding of interleukin 1 and antagonizing effect of insulin. Scand J Immunol. 1984 Jul;20(1):43–51. doi: 10.1111/j.1365-3083.1984.tb00976.x. [DOI] [PubMed] [Google Scholar]
  4. Borel J. F., Feurer C., Magnée C., Stähelin H. Effects of the new anti-lymphocytic peptide cyclosporin A in animals. Immunology. 1977 Jun;32(6):1017–1025. [PMC free article] [PubMed] [Google Scholar]
  5. Braathen L. R., Thorsby E. Human epidermal Langerhans cells are more potent than blood monocytes in inducing some antigen-specific T-cell responses. Br J Dermatol. 1983 Feb;108(2):139–146. doi: 10.1111/j.1365-2133.1983.tb00055.x. [DOI] [PubMed] [Google Scholar]
  6. Calabrese E. J. Gastrointestinal and dermal absorption: interspecies differences. Drug Metab Rev. 1984;15(5-6):1013–1032. doi: 10.3109/03602538409033556. [DOI] [PubMed] [Google Scholar]
  7. Catterall M. D., Addis B. J., Smith J. L., Coode P. E. Sézary syndrome: transformation to a high grade T-cell lymphoma after treatment with Cyclosporin A. Clin Exp Dermatol. 1983 Mar;8(2):159–169. doi: 10.1111/j.1365-2230.1983.tb01760.x. [DOI] [PubMed] [Google Scholar]
  8. Curley R. K., Macfarlane A. W., Vickers C. F. Pyoderma gangrenosum treated with cyclosporin A. Br J Dermatol. 1985 Nov;113(5):601–604. doi: 10.1111/j.1365-2133.1985.tb02385.x. [DOI] [PubMed] [Google Scholar]
  9. Harper J. I., Keat A. C., Staughton R. C. Cyclosporin for psoriasis. Lancet. 1984 Oct 27;2(8409):981–982. doi: 10.1016/s0140-6736(84)91194-2. [DOI] [PubMed] [Google Scholar]
  10. Hess A. D., Tutschka P. J. Effect of cyclosporin A on human lymphocyte responses in vitro. I. CsA allows for the expression of alloantigen-activated suppressor cells while preferentially inhibiting the induction of cytolytic effector lymphocytes in MLR. J Immunol. 1980 Jun;124(6):2601–2608. [PubMed] [Google Scholar]
  11. Horton J. J., Allen M. H., MacDonald D. M. An assessment of Langerhans cell quantification in tissue sections. J Am Acad Dermatol. 1984 Oct;11(4 Pt 1):591–593. doi: 10.1016/s0190-9622(84)70211-8. [DOI] [PubMed] [Google Scholar]
  12. Kupiec-Weglinski J. W., Filho M. A., Strom T. B., Tilney N. L. Sparing of suppressor cells: a critical action of cyclosporine. Transplantation. 1984 Aug;38(2):97–101. doi: 10.1097/00007890-198408000-00001. [DOI] [PubMed] [Google Scholar]
  13. Landegren U., Wigzell H. Cyclosporin A inhibits a discrete step in T-lymphocyte stimulation. Scand J Immunol. 1985 Sep;22(3):279–284. doi: 10.1111/j.1365-3083.1985.tb01882.x. [DOI] [PubMed] [Google Scholar]
  14. LeGrue S. J., Friedman A. W., Kahan B. D. Binding of cyclosporine by human lymphocytes and phospholipid vesicles. J Immunol. 1983 Aug;131(2):712–718. [PubMed] [Google Scholar]
  15. Mueller W., Herrmann B. Cyclosporin A for psoriasis. N Engl J Med. 1979 Sep 6;301(10):555–555. doi: 10.1056/NEJM197909063011016. [DOI] [PubMed] [Google Scholar]
  16. Nelson P. W. Cyclosporine. Surg Gynecol Obstet. 1984 Sep;159(3):297–308. [PubMed] [Google Scholar]
  17. Palacios R. Concanavalin A triggers T lymphocytes by directly interacting with their receptors for activation. J Immunol. 1982 Jan;128(1):337–342. [PubMed] [Google Scholar]
  18. Ryffel B., Willard-Gallo K. E., Tammi K., Loken M. R. Quantitative fluorescence analysis of cyclosporine binding to human leukocytes. Transplantation. 1984 Mar;37(3):276–280. doi: 10.1097/00007890-198403000-00012. [DOI] [PubMed] [Google Scholar]
  19. Scheynius A., Fischer T., Forsum U., Klareskog L. Phenotypic characterization in situ of inflammatory cells in allergic and irritant contact dermatitis in man. Clin Exp Immunol. 1984 Jan;55(1):81–90. [PMC free article] [PubMed] [Google Scholar]
  20. Shevach E. M. The effects of cyclosporin A on the immune system. Annu Rev Immunol. 1985;3:397–423. doi: 10.1146/annurev.iy.03.040185.002145. [DOI] [PubMed] [Google Scholar]
  21. Thivolet J., Barthelemy H., Rigot-Muller G., Bendelac A. Effects of cyclosporin on bullous pemphigoid and pemphigus. Lancet. 1985 Feb 9;1(8424):334–335. doi: 10.1016/s0140-6736(85)91099-2. [DOI] [PubMed] [Google Scholar]
  22. Thompson J. F., Allen R., Morris P. J., Wood R. Skin cancer in renal transplant patients treated with cyclosporin. Lancet. 1985 Jan 19;1(8421):158–159. doi: 10.1016/s0140-6736(85)91922-1. [DOI] [PubMed] [Google Scholar]
  23. Thomson A. W., Aldridge R. D. Absence of dependence on cyclophosphamide-sensitive suppressor cells in suppression of cell-mediated immunity by cyclosporine in the guinea pig. Transplantation. 1984 Jul;38(1):76–77. doi: 10.1097/00007890-198407000-00018. [DOI] [PubMed] [Google Scholar]
  24. Thomson A. W. Immunobiology of cyclosporin A--a review. Aust J Exp Biol Med Sci. 1983 Apr;61(Pt 2):147–172. doi: 10.1038/icb.1983.14. [DOI] [PubMed] [Google Scholar]
  25. Thomson A. W., Moon D. K., Geczy C. L., Nelson D. S. Cyclosporin A inhibits lymphokine production but not the responses of macrophages to lymphokines. Immunology. 1983 Feb;48(2):291–299. [PMC free article] [PubMed] [Google Scholar]
  26. Thomson A. W., Moon D. K., Nelson D. S. Suppression of delayed-type hypersensitivity reactions and lymphokine production by cyclosporin A in the mouse. Clin Exp Immunol. 1983 Jun;52(3):599–606. [PMC free article] [PubMed] [Google Scholar]
  27. Velthuis P. J., Jesserun R. F. Improvement of ichthyosis by cyclosporin. Lancet. 1985 Feb 9;1(8424):335–335. doi: 10.1016/s0140-6736(85)91100-6. [DOI] [PubMed] [Google Scholar]
  28. Wood G. S., Warner N. L., Warnke R. A. Anti-Leu-3/T4 antibodies react with cells of monocyte/macrophage and Langerhans lineage. J Immunol. 1983 Jul;131(1):212–216. [PubMed] [Google Scholar]
  29. van Hooff J. P., Leunissen K. M., vd Staak W. Cyclosporin and psoriasis. Lancet. 1985 Feb 9;1(8424):335–335. doi: 10.1016/s0140-6736(85)91101-8. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES